Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
<h4>Objective</h4>Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic dise...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2016-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0157660&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849417429355069440 |
|---|---|
| author | Tobias Engel Ayer Botrel Otávio Clark Antônio Carlos Lima Pompeo Francisco Flávio Horta Bretas Marcus Vinicius Sadi Ubirajara Ferreira Rodolfo Borges Dos Reis |
| author_facet | Tobias Engel Ayer Botrel Otávio Clark Antônio Carlos Lima Pompeo Francisco Flávio Horta Bretas Marcus Vinicius Sadi Ubirajara Ferreira Rodolfo Borges Dos Reis |
| author_sort | Tobias Engel Ayer Botrel |
| collection | DOAJ |
| description | <h4>Objective</h4>Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).<h4>Methods</h4>Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).<h4>Results</h4>The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue.<h4>Conclusion</h4>The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients. |
| format | Article |
| id | doaj-art-2444dfb3b990490fbcedef23aed5ee3d |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-2444dfb3b990490fbcedef23aed5ee3d2025-08-20T03:32:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01116e015766010.1371/journal.pone.0157660Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.Tobias Engel Ayer BotrelOtávio ClarkAntônio Carlos Lima PompeoFrancisco Flávio Horta BretasMarcus Vinicius SadiUbirajara FerreiraRodolfo Borges Dos Reis<h4>Objective</h4>Prostate cancer is the most common nonskin cancer and second most common cause of cancer mortality in older men in the United States (USA) and Western Europe. Androgen-deprivation therapy alone (ADT) remains the first line of treatment in most cases, for metastatic disease. We performed a systematic review and meta-analysis of all randomized controlled trials (RCT) that compared the efficacy and adverse events profile of a chemohormonal therapy (ADT ± docetaxel) for metastatic hormone-naive prostate cancer (mHNPC).<h4>Methods</h4>Several databases were searched, including MEDLINE, EMBASE, LILACS, and CENTRAL. The primary endpoint was overall survival. Data extracted from the studies were combined by using the hazard ratio (HR) or risk ratio (RR) with their corresponding 95% confidence intervals (95% CI).<h4>Results</h4>The final analysis included 3 trials comprising 2,264 patients (mHNPC). Patients who received the chemohormonal therapy had a longer clinical progression-free survival interval (HR = 0.64; 95% CI: 0.55 to 0.75; p<0.00001), and no heterogeneity (Chi2 = 0.64; df = 1 [p = 0.42]; I2 = 0%). The biochemical progression-free survival (bPFS) also was higher in patients treated with ADT plus docetaxel (HR = 0.63; 95% CI: 0.57 to 0.69; p<0.00001), also with no heterogeneity noted (Chi2 = 0.48; df = 2 [p = 0.79]; I2 = 0%). Finally, the combination of ADT with docetaxel showed a superior overall survival (OS) compared with ADT alone (HR = 0.73; 95% CI: 0.64 to 0.84; p<0.0001), with moderate heterogeneity (Chi2 = 3.84; df = 2 [p = 0.15]; I2 = 48%). A random-effects model analysis was performed, and the results remained favorable to the use of ADT plus docetaxel (HR = 0.73; 95% CI: 0.60 to 0.89; p = 0.002). In the final combined analysis of the high-volume disease patients, the use of the combination therapy also favored an increased overall survival (HR = 0.67; 95% CI: 0.54 to 0.83; p = 0.0003). Regarding adverse events and severe toxicity (grade ≥3), the group receiving the combined therapy had higher rates of neutropenia, febrile neutropenia and fatigue.<h4>Conclusion</h4>The combination of ADT with docetaxel improved the clinical progression-free survival, bPFS and OS of patients with mHNPC. A superior OS was seen especially for patients with metastatic and high-volume disease. This contemporary combination therapy may now be offered as a first-line treatment for selected patients.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0157660&type=printable |
| spellingShingle | Tobias Engel Ayer Botrel Otávio Clark Antônio Carlos Lima Pompeo Francisco Flávio Horta Bretas Marcus Vinicius Sadi Ubirajara Ferreira Rodolfo Borges Dos Reis Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. PLoS ONE |
| title | Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| title_full | Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| title_fullStr | Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| title_full_unstemmed | Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| title_short | Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| title_sort | efficacy and safety of combined androgen deprivation therapy adt and docetaxel compared with adt alone for metastatic hormone naive prostate cancer a systematic review and meta analysis |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0157660&type=printable |
| work_keys_str_mv | AT tobiasengelayerbotrel efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT otavioclark efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT antoniocarloslimapompeo efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT franciscoflaviohortabretas efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT marcusviniciussadi efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT ubirajaraferreira efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis AT rodolfoborgesdosreis efficacyandsafetyofcombinedandrogendeprivationtherapyadtanddocetaxelcomparedwithadtaloneformetastatichormonenaiveprostatecancerasystematicreviewandmetaanalysis |